A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.
- 25 May 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
- 25 May 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.